Fish oil supplementation in diabetic nephropathy prevents: inflammatory and oxidative stress target

Sasongko, H., Nurrochmad, A., Nugroho, A.E. and Rohman, A.

1 Student of Doctoral Program, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, 55281 Indonesia
2 Department of Pharmacy, Universitas Sebelas Maret, Surakarta. 57126 Indonesia
3 Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta, 55281, Indonesia
4 Center of Excellence, Institute for Halal Industry and Systems, Universitas Gadjah Mada, Yogyakarta, Indonesia

Abstract

Diabetic nephropathy is a major cause of progressive kidney disease and end-stage renal disease. The major treatment strategy for the prevention and cure of diabetic nephropathy development and progression is based on the management of blood glucose, blood pressure, lipids, oxidative stress, and inflammation. Fish oil is important for human health because of its high content of polyunsaturated fatty acids like omega-3. Inflammatory and oxidative stress pathways are potential targets of omega-3 fish oil for the development of diabetic nephropathy. Many studies have proven the activity of fish oil for both single and adjuvant therapy. However, not all experiments on animal models are effective in human research. This review provides thoughts on progress in research on a preclinical and clinical study of fish oil as a diabetic nephropathy therapy. According to a literature search, fish oil inhibits inflammation, specifically tumour necrosis factor-α, interleukin-1, interleukin-6, and nuclear factor-κB. Several markers have an influence on oxidative stress, including glutathione, superoxide dismutase-1, catalase, glutathione peroxidase-1, glutathione reductase, and malondialdehyde. Several investigations have shown that research findings in experimental animals are not always the same as those in clinical trials. The main findings of this review were to identify the main causes of oxidative stress and inflammation from the use of fish oil in the prevention of diabetic nephropathy. Different results were found in several animal experiments and clinical tests, but they should be considered when treating diabetes. In the future, things like where the oil comes from and how good the fish oil is must also be considered carefully.

1. Introduction

Diabetic kidney disease or diabetic nephropathy (DN) is one of the main complications of diabetes mellitus (DM), characterized by oxidative stress, inflammatory response, thickening of basement membranes, fibrosis, necrosis, albuminuria, and renal dysfunction (Kishore et al., 2020; Cao et al., 2022). The number of cases of DM in the world with uncontrolled blood sugar levels causing complications is increasing, especially in the kidneys. Many studies have found that DN occurs in more than 40% of diabetic patients (Hu et al., 2017; Lima et al., 2022) and accounts for roughly 45% of new cases of end-stage renal disease (Domingueti et al., 2016). Although the pathogenesis of DN is unknown, irregularities in glucose and lipid metabolism are important to comprehend; chronic exposure of renal cells to glucose overload and lipids causes oxidative stress, inflammation, and intracellular hypoxia, eventually leading to interstitial fibrosis, glomerular hyperfiltration, and glomerulosclerosis, which later set the stage for DN (Adelusi et al., 2020; Ayinde et al., 2020; Chaudhuri et al., 2022)

Controlling blood glucose levels and blocking the renin-angiotensin system are the major treatment approaches for treating or preventing the development and progression of DN (Ni et al., 2019). Despite this, the disease incidence rate continues to rise due to poor effectiveness of treatments and a slew of severe side effects. Although currently available anti-diabetic
medications such as biguanides and sulfonylureas are effective in controlling hyperglycemia, they are unable to entirely prevent the onset and progression of associated consequences (Gurumallu et al., 2022). Because of the extremely long course and incurable character of diabetes, lifetime usage of anti-diabetic medicines is currently the global strategy to diabetes therapy (Huang et al., 2020). Due to treatment-related financial pressures and medication side effects, the majority of patients do not adhere to these therapeutic measures (Zaccardi et al., 2016).

The development of novel, effective, and safer therapeutic options that target glycemic management, oxidative stress inhibition, and inflammatory pathways involved in the evolution of DN has recently gained a lot of attention (Ni et al., 2019). As a result, new treatments with hypoglycemic, antioxidant, and anti-inflammatory properties may provide protection against DN (Abou-Hany et al., 2018; Xu et al., 2018). Fish oil contains omega-3 polyunsaturated fatty acids (n-3 PUFA) acts as an antioxidant supplement (Jiang et al., 2019), and anti-inflammation (Crupi and Cuzzocrea, 2022; Sasongko et al., 2019). Omega-3 polyunsaturated fatty acids have been demonstrated in clinical research to be beneficial in reducing inflammatory conditions in renal diseases (Keapai et al., 2016; Méndez-Morales et al., 2022) by competing with the enzymatic metabolism of arachidonic acid, which is transformed to pro-inflammatory eicosanoids such as prostaglandins, thromboxane, and leukotrienes, long chain n-3 PUFA regulate inflammatory pathways (Gebauer et al., 2006). Unsaturated fatty acids, such as monounsaturated fatty acids (MUFAs) and polyunsaturated fatty acids (PUFAs), have been found to increase insulin sensitivity (Gao et al., 2017). The beneficial effects of activity as anti-inflammatory and oxidative stress have demonstrated that omega 3 fatty acids can prevent kidney injury in cases of diabetes (Jangalé et al., 2016; Ghadge et al., 2016; Rashidi et al., 2020). Recent studies have proven the nephroprotective activity of fish oil containing n-3 PUFA for both monotherapy and adjuvant therapy. However, not all experiments on animal models are effective in human studies (Itsiopoulos et al., 2018). The novelty of this review is the discovery of major markers of oxidative stress and inflammation pathways in the application of fish oil for the prevention of DN. From these findings, the researchers were able to directly determine the target parameters without screening all markers in clinical or pre-clinical study.

The aim of this review was to provide an insight into advances in research on pre-clinical and clinical studies of fish oil as a therapy for DN. Furthermore, practical considerations regarding fish oil supplementation on nephroprotective effects including fatty acid profile, dose, route of administration, duration of treatment, population, and markers, will be discussed.

2. Diabetic nephropathy

Diabetic nephropathy has a wide range of clinical and pathophysiological manifestations. Hyperglycemia causes degenerative changes such as glomerular hyperfiltration, epithelial hypertrophy, and microalbuminuria, which is followed by glomerular basement membrane thickening, mesangial matrix buildup, and overt proteinuria, and finally glomerulosclerosis and end-stage renal disease.

![Figure 1. Metabolic pathways involved in the development of diabetic nephropathy. PKC: protein kinase C, AGES: advanced glycation end products, RAAS: renin angiotensin aldosterone system, VEGF: vascular endothelial growth factor, ROS: reactive oxygen species, TGF-β: transforming growth factor-beta (Vinod, 2012)](https://doi.org/10.26656/fr.2017.7(2).220)
vasoconstriction, and DNA damage (Vinod, 2012). A high quantity of ROS can stimulate numerous molecular mechanisms and impair the activity of antioxidant enzymes, which can lead to illnesses like DN (Bohlouli et al., 2021). Under normal conditions, ROS are important in processes such as cell signaling, aging, and degenerative diseases (Hajam et al., 2022; Singh et al., 2022). The kidney is especially vulnerable to damage from high blood glucose levels. The nephron (glomeruli and tubuli) is an insulin-independent organ, and the circulatory glucose concentration in the environment and the expression of glucose facilitators control the glucose flow to cells (Ravindran and Munusamy, 2022).

4. Inflammation

Inflammation is also linked to the development of DN. Multiple studies have found considerably higher circulating inflammatory mediators, as well as increased immune cell infiltration and levels of adhesion molecules and chemokines in the kidneys of DN animal models and humans, indicating that inflammation plays a role in the development of DN (Zheng and Zheng, 2016; Pérez-Morales et al., 2019). Major production of inflammatory markers and an accumulation of inflammatory cells were identified in the renal tissue of patients with DN (Eisa et al., 2021). As nephropathy progresses, these components' concentrations increase, and they've all been associated with increased albumin levels in the urine and clinical signs of glomerular and tubulointerstitial injury (Donate-Correa et al., 2020). As a result, anti-inflammatory substances may have the ability to alleviate DN (Liao et al., 2022).

5. Fish oil

Fish is one of the natural resources that contain essential fatty acids (FAs) for health (Sasongko et al., 2018), and many studies have been carried out to be developed as drugs and supplements (Rizliya and Mendis, 2014; Sasongko et al., 2021). Lipids in fish oil are mainly available as triacylglycerols (TAGs). Glycerol carbon atoms are counted with the stereochmical system, with the locations sn-1 and sn-3 outer, with the center position sn-2 (Alfio et al., 2021). The lipid classes are different: saturated FAs (SFAs), monounsaturated FAs (MUFS), and polyunsaturated FAs (PUFS). Different types of FAs are found in lipids (PUFS, containing more than one C-C double bond) and MUFS (having one C-C double bond) (Zhang et al., 2020). In general, the lipids of fish vary considerably according to their geographical location, kind of water, diet, season and ripe fish (Nurnadja et al., 2011). Recent studies have shown the renoprotective benefits of a fish diet and supplementation with fish oil. Several studies show that omega-3 FAs can reduce inflammation. They may do so by enhancing anti-inflammatory and antioxidant components or compounds in the body. The following Tables 1 and 2 summarize the general features of the studies covered.

All polyunsaturated fatty acids (PUFS) may be synthesized by humans except two: linoleic acid (LA) and -linolenic acid (ALA), which are considered essential fatty acids and must be obtained from dietary consumption. LA is a precursor to the omega-6 fatty acid, whereas ALA is a precursor to the omega-3 compounds (Mullin et al., 2021). Omega-3 unsaturated fatty acids containing eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are reported to have various biological activities such as anti-inflammatory, cardiovascular, and metabolic diseases (Zhou et al., 2021), (Sasongko et al., 2018). In the stomach and throughout the body, omega-3 PUFS have anti-inflammatory and immunoregulatory effects (Parian et al., 2015). The cyclooxygenase (COX) pathway (specifically COX-2), which generates prostaglandin E-2, a pain and inflammation promoter, is downregulated by omega-3 fatty acids. This route often uses arachidonic acid (AA) as a substrate. EPA is a chemical homologue that varies from AA solely in the presence of the n3 double bond. It acts as a substitute substrate for COX and reduces the consumption of AA as a substrate for the COX enzyme. EPA also suppresses the 5-lipoxygenase pathway, which results in lower levels of proinflammatory leukotriene B4 in the body (Wild et al., 2007). EPA and DHA are precursors for the synthesis of resolvins, which are generated to stop the neutrophil invasion, stimulate macrophage elimination of apoptotic cells, and promote tissue remodeling and homeostasis (Serhan et al., 2004). Omega-6 fatty acids, such as LA, on the other hand, are more prone to proinflammatory activities (Ananthakrishnan et al., 2013; Mullin and Limketkai, 2021). At various phases of inflammation, lipid mediators generated from omega-6 PUFA AA are implicated. Several lipid mediators, including the eicosanoids prostaglandins (PGs), thromboxanes (TXs), and leukotrienes (LTs), govern the onset of acute inflammation, modulating blood flow, endothelial permeability, polymorphonuclear neutrophil (PMN) chemotaxis, and blood clotting (Flower, 2006). The enzymes cyclooxygenase (COX) and lipoxygenase (LO) mediate the transformation of AA into a variety of proinflammatory mediators such as PGs, prostacyclin (PGI2), TXA2, and pro-inflammatory leukotrienes, commonly known as 4-series leukotrienes (Funk, 2001; Powell and Rokach, 2015). Omega-3 fatty acids have been shown to modulate gut immunity by reducing proinflammatory cytokines such as interleukin (IL)-1 and tumor necrosis factor (TNF)-α, as well as the peroxisome
proliferator-activated receptor/nuclear transcription factor kappa-beta (PPAR-α/NF-κB), and improving epithelial barrier function and mucosal healing (Mullin et al., 2021).

7. Fish oil in oxidative stress targets

Oxidative stress is an imbalance between endogenous antioxidant enzymes and free radicals (Lobo et al., 2010). At the cellular level, DM causes renal mitochondrial injury and upregulates inducible nitric oxide synthase (iNOS), resulting in increased levels of ROS and reactive nitrogen species (RNS) due to lipid peroxidation and protein carbonylation (Taslimi and Gülçin, 2018; Gülcin, 2020; Stanton, 2021). ROS promotes inflammation by activating a variety of redox and inflammatory signaling pathways, including nuclear factor (NF)-κappa β (Mayyas et al., 2019). Fish oil contains omega-3 PUFAs, which are antioxidants that influence lipid mediators and signaling pathways (Adkins and Kelley, 2010). Omega-3 PUFAs decrease oxidative stress in human and animal models by boosting antioxidant levels of superoxide dismutase (SOD) and glutathione (GSH) (Taneda et al., 2010; Jangale et al., 2016). GSH is an essential endogenous antioxidant for the detoxification of reactive oxygen species (ROS) and the maintenance of intracellular redox balance (Asgher et al., 2017).

8. Conclusion

The main finding of this review is to identify the main makers of oxidative stress and inflammation from the use of fish oil in the prevention of DN. Different results were found in several animal experiments and clinical tests, but they should be taken into account when treating diabetes. In future tests, the source of the oil and the quality of the fish oil must be considered.

Conflict of interest
The authors declare no conflict of interest.

Acknowledgments
The authors would like to thank the Universitas Gadjah Mada for funding through the scheme of Rekognisi Tugas Akhir (RTA) 2022 contract number: 2920/UN1/DITLIT/Dit-Lit/PT.01.05/2022 awarded to

---

Table 1. Clinical trials and meta-analyses of fish oil enriched omega-3 in diabetic nephropathy

<table>
<thead>
<tr>
<th>Sample</th>
<th>Study Population</th>
<th>Methods</th>
<th>Duration</th>
<th>Dose</th>
<th>Clinical Outcomes in Inflammatory and/ or oxidative stress</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fish oil</td>
<td>32 overweight or obese patients (18 women and 14 men)</td>
<td>A pre-post pilot study in Brazil</td>
<td>8 weeks</td>
<td>Four times 2400 mg/day</td>
<td>↓ TNFα, ↓ IL-1β, and ↓ IL-6</td>
<td>Souza et al. (2020)</td>
</tr>
<tr>
<td>Omega-3 PUFAs soft gels containing 600 mg EPA and 300 DHA</td>
<td>61 patients (30 placebo – 31 interventions) in T2DM</td>
<td>Double-blind randomised placebo-controlled clinical trial in Iran</td>
<td>10 weeks</td>
<td>Three soft gels/day</td>
<td>↑ Ferric reducing ability of plasma (FRAP), induction antioxidant gene expression of NRF2, and ↓</td>
<td>Golpour et al. (2020)</td>
</tr>
<tr>
<td>Omega-3 capsules</td>
<td>44 patients (22 placebo – 22 intervention) in T2DM with nonalcoholic fatty liver disease</td>
<td>Randomized double-blind clinical trial in Iran</td>
<td>12 weeks</td>
<td>Twice omega-3 capsules (1000 mg)/day</td>
<td>↑ IL-6</td>
<td>Orang et al. (2020)</td>
</tr>
<tr>
<td>Omega-3</td>
<td>1312 Inclusion criteria in T2DM patients</td>
<td>Double-blind randomised placebo-controlled clinical trial</td>
<td>5.3 years</td>
<td>One gram of Omega-3 FA daily (Omacor, 465 mg EPA + 375 mg DHA)</td>
<td>Not significant reduce concentrations of inflammatory biomarkers (IL-6, hsCRP or NT-proBNP)</td>
<td>Limonte et al. (2021)</td>
</tr>
</tbody>
</table>

Symbols ↑ or ↓ = significantly different compared with placebo group or before treatment (pretest)
Table 2. *In-vivo* study of fish oil enriched omega-3 in diabetic nephropathy

<table>
<thead>
<tr>
<th>Sample</th>
<th>Animals</th>
<th>Duration</th>
<th>Dose</th>
<th>Inflammatory markers</th>
<th>Oxidative stress markers</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fish Oil</td>
<td>Wistar rats</td>
<td>35 days</td>
<td>10% w/w FO mixed with pellets</td>
<td>↓ mRNA expression of IL-6, and NF-kB</td>
<td>↓ TBARS, ↑ CAT, not significantly with SOD, mRNA expression of SOD-1, and GPx-1, and ↑ mRNA expression of CAT</td>
<td>Jangale et al. (2016)</td>
</tr>
<tr>
<td>Omega-3</td>
<td>Wistar rats</td>
<td>8 weeks</td>
<td>415 mg/kg/day, 5 times/week</td>
<td>↓ TNF-α, ↓ IL-1β, and ↓ IL-6</td>
<td>↑ GSH, ↑ SOD1, ↑ CAT, ↑ GPx1, ↑ GR, ↓ MDA, and ↓</td>
<td>El-Boshy et al. (2021)</td>
</tr>
<tr>
<td>Omega-3 fish oil (containing EPA 180 mg and DHA 120 mg)</td>
<td>Sprague-Dawley rats</td>
<td>4 weeks</td>
<td>Omega-3 fish oil (10% W/W diet)</td>
<td>n/a</td>
<td>↓ MDA</td>
<td>Eraky et al. (2018)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fish Oil</td>
<td>Male LDLr&lt;sup&gt;−/−&lt;/sup&gt;/ApoB&lt;sup&gt;100/100&lt;/sup&gt; mice</td>
<td>8-11 weeks</td>
<td>Fish oil contains 44% EPA and 25% DHA mix with feed</td>
<td>↓ TNF-α, ↓ IL-1β, and ↓ iNOS gene expression</td>
<td>n/a</td>
<td>Perazza et al. (2021)</td>
</tr>
<tr>
<td>Ethyl eicosapentaenoate (EPA-E)</td>
<td>Male C57/BL6 mice</td>
<td>19 weeks</td>
<td>1000 mg/kg body weight/day of EPA-E</td>
<td>n/a</td>
<td>↓ MDA, ↓ mRNA expression of p47phox, Nox2, and Nox4 in renal</td>
<td>Yasuzawa et al. (2021)</td>
</tr>
<tr>
<td>Fish oil</td>
<td>Wistar rats</td>
<td>4 weeks</td>
<td>3000 mg/kg body weight/day</td>
<td>n/a</td>
<td>↓ MDA and ↑ CAT</td>
<td>Parveen et al. (2019)</td>
</tr>
<tr>
<td>Fish oil</td>
<td>Wistar rats</td>
<td>4 weeks</td>
<td>2.5% of fish oil supplements containing 16% EPA and 19%</td>
<td>n/a</td>
<td>↓ MDA</td>
<td>Vitlov Uljević et al. (2019)</td>
</tr>
</tbody>
</table>

Symbols ↑ or ↓ = significantly different compared with diabetic group.

Prof. Dr. Abdul Rohman

References


Role and Regulation under Abiotic Stress, p. 297–313. Singapore: Springer. https://doi.org/10.1007/978-981-10-5254-5_12


Serhan, C.N., Arita, M., Hong, S. and Gotlinger, K.
MINI REVIEW


